A group of a billion species or benefit was born
The eight listed companies have been promoted in the market promotion prospects of the eight listed companies.
From the magnitude of sales revenue, there is a potential to grow to 1 billion or even 2 billion varieties for greelo, apatinib, and compaq. The recombinant human brain natriuretic peptide, due to the low market penetration rate due to price, is expected to reach 765 million yuan by 2020. Temple, sand ester as listed in 2014 and the price is higher, sales had not, after joining insurance sales revenue is expected to increase 3-5 times than before, is expected to reach 500 million yuan in 2020, sales of scale; However, the recombinant human urokinase and the compound yellow dyer films have a relatively small number of patients, and the future market space is about 100 million yuan - 200 million yuan.
It is believed to be used in the treatment of hypertension. According to the Chinese nutrition and chronic diseases among residents report 2015, 2012, 18 and older adults in China hypertension incidence was 25.3%, thus can calculate the number of hypertension patients in China is about 2012, 252 million. Jiang Weina analysis, according to each take one tablet daily 240 mg patients with specifications of the temple, sand ester and its in 2017, the lowest price is 9.13 yuan/piece (240 mg), consider the intermediate links and distribution fees were 10%, 10% VAT, o is the sand ester the ex-factory price of 7.09 yuan/piece. Negotiations in medicare catalog price 7.05 yuan/piece, the temple, sand ester the ex-factory price of 5.48 yuan/piece, as this calculation, the temple, sand ester piece has broken one billion yuan, the current market space and hypertension crowd maintained an average annual growth of around 4%.
The recombinant human urokinase (puyouk) of the natural force, according to the instruction, puyouk's indication is the thrombolytic therapy for acute st-segment elevation myocardial infarction. According to the 2015 report of China's cardiovascular disease report, the cost of hospitalization in 2014 was 13375 million yuan, with a total hospitalization rate of 24,706 yuan, which was calculated as 55.67 million patients who were hospitalized in 2014. In patients with myocardial infarction, about 50% of patients with STEMI and NSTEMI have been analyzed, according to the analysis. Among them, about 12% of STEMI patients admitted to the hospital received pure thrombolytic therapy, 7.5% of thrombolytic + PCI, 48.9% of PCI, 28.8% did not receive any reperfusion therapy. Thus, about 10.86 million people received thrombolytic treatment in 2014. Puyouk dosage is 50mg (5mg/branch * 10 /, 1 box). The minimum bidding price of 2016-2017 is 1152 yuan/branch, and the medical insurance negotiation will be paid RMB 1020/5mg, considering the 10% distribution fee and 17% value-added tax, which will be included in the post-medical insurance price of 792 yuan / 5mg.
The compound yellow tablets of yifan medicine are mainly used in APL. According to the Chinese journal of epidemiology, the incidence of leukemia in China was 6.7/100,000 in 2013. Compound Huang Dai piece of medical insurance to pay the price of 10.5 yuan (0.27 g/piece), using the direct selling company sales distribution, the combination of considering the APL patients mainly in large hospitals and the drug shorter time to market, assuming all adopt the direct sales way, only calculate 10% distribution fee and 17% VAT, expands a single treatment after sales income is 11087 yuan.
Compaq is mainly used to treat age-related macular degeneration (AMD). According to novartis data, the incidence of AMD is 11% in developed countries, with wAMD accounting for about 12%, and the incidence of AMD is close to developed countries in China. According to the sixth census data, China has a total population of 1.37 billion, with 20% of the population over the age of 50. It is estimated that AMD has a population of 3.014 million. Among them, the number of patients in wAMD is about 3.6 million. Compaq heap in 2017, the lowest price is 2017 yuan /, assume shipping costs accounted for 10%, middle exclude the and consider 17% of value added tax, calculated on negotiation price 5550 yuan /, compaq heap of ex-factory price at RMB 4312.35 / teams.
The recombinant human brain natriuretic peptide (xin xin) in the Tibetan pharmaceutical industry is also on the list, which is a medicine for the cardiovascular field. China's cardiovascular disease report 2014 shows that about 290 million people in China have cardiovascular disease, and the average annual growth rate of patients with cardiovascular disease in China from 1980 to 2013 was 9.5%. In the clinical use of new live hormone, each patient was first injected with a 1.5ug/kg intravenous attack, followed by a continuous intravenous drip of 0.0075 ug/kg/min for 24 hours. The price of the new live health care catalog is 585 yuan per branch, and the factory price is about 455 yuan.
The apatinib of hengrui medicine is the most important medicine in the field of gastric cancer. According to the literature "Cancer Statistics in China 2015", in 2015, 679, 000 people were expected to have new cases of stomach Cancer, and 60 to 80 percent of patients with gastric Cancer were diagnosed with advanced stage. Apatinib clinical recommended dose of 850mg, once a day. The duration of treatment is continuous, until the disease progresses or an untolerated adverse reaction occurs. Apatinib negotiated a payment of 2858 yuan/box, considering 10% distribution and 17% VAT, estimated at $2221 per box. According to the previous calculation of the use of individual patients, the amount of medication for a single patient was about 24,748 yuan.
More policy support is needed to encourage drug innovation
The list of drugs announced by the ministry of human resources and social security has delighted the domestic and foreign countries, with a number of new drugs on the list, and prices are protected by maximum protection. Foreign drugs have been killed in this negotiation, which fully demonstrates the support for domestic innovative drugs at the policy level, which is conducive to leading industrial innovation and encouraging enterprise innovation.
Innovative drugs have become more highly valued in the past two years. In August 2015, the food and drug administration issued a review and approval system for the review and approval of pharmaceutical medical devices.
But policy alone will not clear the way for the development of innovative drugs. The company has gone through thousands of hardships and ran out of money to develop a new drug, hoping it will make a profit. The premise of profit is to have a market first, but at present, the innovation medicine in our country medicine industry, it is a lot of difficulties to promote. In the current bidding system, the price of who is low is the winner, the price competition is terrible. The advantages of original pharmaceutical and individual pricing drugs are no longer.
Hospitals make up 80% of the market for drugs, and hospitals have to go through provincial bids before entering the hospital. In the local bidding process, some unreasonable bidding system keeps many innovative drugs out of the door. On the one hand, the bidding process in the provinces is slow and irregular, the longest is five years. This means that innovative drugs marketed during this period cannot be sold in hospitals in these places. Is dominated by the government, on the other hand, the drug centralized bidding purpose is through the competition in the market, let patients with high quality and low price of choose and buy drugs, but in the process of actual execution appeared the tendency of the low price is only take ", eventually leading to bad money after bad money, prices slightly higher innovation medicine is often blocked in the tender.
An innovative drug won't mean it can be sold in the hospital. It must be approved by the hospital pharmacy committee. The approval of the pharmaceutical committee is similar to that of drug tenders. There is no uniform regulation of the approval cycle of the new drug, and some hospital pharmacy committees only open once every six months, some two or three years. At the same time, because of the different levels of members of the pharmaceutical committee, many doctors know little about China's newly developed targeted drugs, which limit the access of new drugs to hospitals.
And finally, health care. Innovative drugs can only be used by more patients if they are included in the national health care catalog. The existing national health care directory is updated every four to five years, and the innovative drugs that are listed on the market will be included only when the health care catalog is updated, and the bad luck will be four or five years. In addition, the current health care medicines within the directory is in proportion to submit an expense account, this leads to originally similar varieties pays part of the price gap is big, it makes doctors and patients to choose your medicine, imported drugs, not only increased the national financial burden, also let the innovation of the domestic medicine have nowhere to go.
As a result of the above pass, 30% of the innovative drugs are still unable to enter any province after two years of marketing; Innovative drugs that can be sold in 1-5 provinces, accounting for only 25 per cent of the total number of approvals; Less than 20 percent of the 15 provinces sold. In particular, more than half of the innovative drugs in the first year of the market are not accessible to any province.
The health care negotiation catalogue, launched by the ministry of human resources, is a new way to encourage domestic drug companies to innovate. The apatinib and kanghong pharmaceutical products of hengrui medicine even give a super - expected price. This is a respect for innovators and a focus on intellectual property, encouraging domestic companies to develop new drugs and make better and cheaper medicines.
|
